OS Therapies’ (OSTX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of OS Therapies (NYSEAMERICAN:OSTX) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $20.00 price objective on the stock.

Other equities research analysts have also issued research reports about the company. Lake Street Capital lowered their price objective on OS Therapies from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Zacks Research raised OS Therapies from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $18.50.

OS Therapies Stock Down 4.9%

Shares of OS Therapies stock opened at $1.55 on Monday. The firm has a market cap of $54.58 million, a price-to-earnings ratio of -1.89 and a beta of -3.80. OS Therapies has a 52-week low of $1.12 and a 52-week high of $2.57. The company’s 50-day simple moving average is $1.40 and its 200-day simple moving average is $1.74.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP acquired a new position in OS Therapies during the third quarter worth about $29,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of OS Therapies during the 3rd quarter worth approximately $40,000. Ground Swell Capital LLC purchased a new position in shares of OS Therapies during the 3rd quarter worth approximately $40,000. Bridgeway Capital Management LLC acquired a new position in shares of OS Therapies during the 2nd quarter worth approximately $47,000. Finally, Jane Street Group LLC acquired a new position in shares of OS Therapies during the 4th quarter worth approximately $39,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.